Part of this work was presented as abstract to the 60th annual meeting of the American Society of Hematology, San Diego, CA, December 2018 (Abstract # 4 4 42).The diagnosis and risk stratification of multiple myeloma (MM) is based on clinical and cytogenetic tests. Magnetic CD138 enrichment followed by interphase FISH (fluorescence in situ hybridisation) is the gold standard to identify prognostic translocations and copy number alterations (CNA). Although clinical implications of gene expression profiling (GEP) or panel based sequencing results are evident, those tests have not yet reached routine clinical application. We set up a single workflow to analyse MM of 211 patients at first diagnosis by whole genome sequencing (WGS) and RNA-Seq a...
Genomic lesions are not investigated during routine diagnostic workup for multiple myeloma (MM). Cyt...
Multiple Myeloma (MM) is a disease with highly variable clinical presentation and outcome due to the...
Minimal residual disease (MRD) is one of the most powerful prognostic factors in multiple myeloma. T...
Background: Multiple myeloma is a genetically complex disease where early hits include chromosome 14...
Multiple myeloma (MM) is one of the plasma cell-related hematological malignancies exceeding 10.0% o...
The standard approach to multiple myeloma relies on marrow morphology, serum and urine biochemistry ...
At diagnosis, Multiple Myeloma (MM) is traditionally classified into two clinical and prognostic sub...
Introduction: Multiple myeloma is a fatal malignant proliferation of clonal bone marrow Ig-secreting...
Multiple myeloma (MM) cells are hypoproliferative and thus 70% of MM cases are not detected in conve...
Multiple myeloma (MM) cells are hypoproliferative and thus 70% of MM cases are not detected in conve...
International audienceGenomic lesions are not investigated during routine diagnostic workup for mult...
Introduction Although monoclonal immunoglobulin (Ig) production by myeloma cells is one of the centr...
International audienceGenomic lesions are not investigated during routine diagnostic workup for mult...
International audienceGenomic lesions are not investigated during routine diagnostic workup for mult...
Copyright © 2019 Yao, Bai, Orfao and Chim.Next-generation sequencing (NGS) has been applied to monit...
Genomic lesions are not investigated during routine diagnostic workup for multiple myeloma (MM). Cyt...
Multiple Myeloma (MM) is a disease with highly variable clinical presentation and outcome due to the...
Minimal residual disease (MRD) is one of the most powerful prognostic factors in multiple myeloma. T...
Background: Multiple myeloma is a genetically complex disease where early hits include chromosome 14...
Multiple myeloma (MM) is one of the plasma cell-related hematological malignancies exceeding 10.0% o...
The standard approach to multiple myeloma relies on marrow morphology, serum and urine biochemistry ...
At diagnosis, Multiple Myeloma (MM) is traditionally classified into two clinical and prognostic sub...
Introduction: Multiple myeloma is a fatal malignant proliferation of clonal bone marrow Ig-secreting...
Multiple myeloma (MM) cells are hypoproliferative and thus 70% of MM cases are not detected in conve...
Multiple myeloma (MM) cells are hypoproliferative and thus 70% of MM cases are not detected in conve...
International audienceGenomic lesions are not investigated during routine diagnostic workup for mult...
Introduction Although monoclonal immunoglobulin (Ig) production by myeloma cells is one of the centr...
International audienceGenomic lesions are not investigated during routine diagnostic workup for mult...
International audienceGenomic lesions are not investigated during routine diagnostic workup for mult...
Copyright © 2019 Yao, Bai, Orfao and Chim.Next-generation sequencing (NGS) has been applied to monit...
Genomic lesions are not investigated during routine diagnostic workup for multiple myeloma (MM). Cyt...
Multiple Myeloma (MM) is a disease with highly variable clinical presentation and outcome due to the...
Minimal residual disease (MRD) is one of the most powerful prognostic factors in multiple myeloma. T...